Pestalozzi advises Johnson & Johnson on the CHF 30 million capital increase for the acquisition of an equity stake in Biocartis SA
Johnson & Johnson took an equity stake in Biocartis, a commercial stage molecular diagnostics (MDx) company. For this purpose it increased its capital by CHF 30 million. Pestalozzi advised Johnson & Johnson on its role as co-investor.